Treatment G

DRUG5 trials

Sponsors

Pfizer, Gilead Sciences, AstraZeneca

Conditions

Chronic Lymphocytic LeukemiaHealthyHealthy VolunteersHeart FailurePharmacokinetics

Phase 1

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

CompletedNCT01181700

PfizerPharmacokinetics

Start: 2010-10-31End: 2011-01-31Updated: 2011-01-24

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

CompletedNCT01272375

Start: 2011-01-31End: 2011-05-31Updated: 2018-12-03

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

CompletedNCT01841489

Gilead SciencesChronic Lymphocytic Leukemia

Start: 2013-05-31End: 2013-10-31Updated: 2014-02-07

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

CompletedNCT03978143

PfizerHealthy Volunteers

Start: 2019-06-12End: 2019-10-17Updated: 2019-11-15

Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers

CompletedNCT04798222

AstraZenecaHeart Failure

Start: 2021-06-29End: 2021-09-03Updated: 2021-09-09

Related Papers

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation.

2026-04-01

Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease.

2025-09-18